Shares of Kaleido Biosciences Inc (NASDAQ:KLDO) have been given a consensus rating of “Buy” by the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $17.70.

Separately, Zacks Investment Research cut Kaleido Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, August 20th.

Shares of NASDAQ KLDO traded up $0.25 during midday trading on Friday, reaching $9.20. The company’s stock had a trading volume of 5,693 shares, compared to its average volume of 72,897. The stock’s 50 day moving average price is $8.47. Kaleido Biosciences has a fifty-two week low of $6.23 and a fifty-two week high of $19.00.

Kaleido Biosciences (NASDAQ:KLDO) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.09). Research analysts predict that Kaleido Biosciences will post -3.28 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in KLDO. Vanguard Group Inc. acquired a new position in shares of Kaleido Biosciences during the 2nd quarter worth $1,061,000. Tower Research Capital LLC TRC bought a new position in shares of Kaleido Biosciences in the second quarter valued at $56,000. BlackRock Inc. bought a new position in shares of Kaleido Biosciences in the second quarter valued at $2,835,000. Northern Trust Corp bought a new position in shares of Kaleido Biosciences in the second quarter valued at $145,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Kaleido Biosciences during the second quarter valued at about $353,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

About Kaleido Biosciences

Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.

Featured Article: Accumulation/Distribution

Analyst Recommendations for Kaleido Biosciences (NASDAQ:KLDO)

Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.